Search company, investor...

Minomic International


Unattributed | Alive

Total Raised


Last Raised

$6.8M | 6 yrs ago

About Minomic International

Minomic International specializes in the development and commercialization of diagnostic products.

Headquarters Location

75 Talavera Road Suite 2

Macquarie Park, New South Wales, 2113,


Missing: Minomic International's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Minomic International's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Minomic International

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Minomic International is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,562 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,535 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items

Minomic International Patents

Minomic International has filed 1 patent.

The 3 most popular patent topics include:

  • Body fluids
  • Clusters of differentiation
  • Diabetes
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Immunology, Transcription factors


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Immunology, Transcription factors



Latest Minomic International News

20/20 GeneSystems Launches First Accelerator Facility for Innovative Clinical Lab Tests

Sep 28, 2021

Shared CLIA lab to help diagnostics start-ups, including Australian-based Minomic, more rapidly enter the U.S. market September 28, 2021 09:19 AM Eastern Daylight Time ATLANTA--( BUSINESS WIRE )-- 20/20 GeneSystems, Inc. , (“20/20”), announced the launch of its Clinical Lab Innovation Axcellerator (CLIAx) , believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the U.S. “Establishing and maintaining a compliant CLIA lab can be costly and daunting for young companies, especially those seeking to enter the American market from overseas,” 20/20 President and CEO, Jonathan Cohen said. “From leasing facilities to hiring qualified laboratory professionals, purchasing equipment, and running daily operations, it can be a hefty burden. These hurdles can limit or delay our nation’s access to some of the most creative and out-of-the-box testing solutions from around the world demonstrated during the pandemic to be in great demand. Our unique CLIA Axcellerator removes or lowers many of the barriers in the path of these innovators.” CLIAx offers nearly 3,000 square feet of ready-to-use communal clinical laboratory space and testing equipment, including a full PCR/molecular assay suite, NextGen Sequencing (NGS), immunoassay, and clinical chemistry capabilities. Importantly, 20/20’s marketing and sales teams will help promote the new tests introduced by CLIAx’s clients to the market segments in which 20/20 is currently active. Earlier this month the company signed an agreement with Australian-based Minomic International Ltd , a diagnostics firm that is gearing up to introduce MiCheck® Prostate, a blood test that uses proprietary algorithms and biomarkers to estimate the risk of aggressive prostate cancer. “Our company is so excited to be working with the CLIAx team. Their clinical lab accelerator is a unique concept that allows us to tap into the expertise in laboratory testing. It is just what Minomic requires - a ‘soft landing’ site to enter the U.S. market so we can focus on the key activity of test rollout instead of the necessary minutiae of setting up and running a lab service,” said Dr. Brad Walsh, CEO of Minomic International Ltd. CLIAx was officially designated by the Maryland Department of Commerce as a “Soft Landing” program for overseas companies seeking to enter the U.S. market. “Maryland is 'open' for international companies looking to expand, and the new Clinical Laboratory Innovation Axcellerator will provide the perfect soft landing for those seeking to explore the U.S. market," said Maryland Commerce Secretary Kelly M. Schulz. "We applaud 20/20 GeneSystems for taking the lead with this initiative and we hope to see similar spaces launch throughout the state." For more information, visit . About 20/20 GeneSystems: 20/20 GeneSystems, Inc. ( ) is a Rockville, Maryland-based company dedicated to modernizing clinical lab testing through machine learning and real-world data. The company ranked #770 on the 2021 Inc.5000 list of America’s fastest growing companies. 20/20 currently offers OneTest , a blood test to aid in the early detection of multiple cancers as well as several COVID-19 testing solutions including viral tests based on PCR and point-of-care, rapid antibody and antigen tests. About Minomic International Ltd: Minomic International Ltd is an Australian diagnostic company specializing in development of diagnostics for solid tumors, including prostate, bladder and pancreas. Minomic has developed the in vitro diagnostic MiCheck® Prostate test for the early detection of aggressive prostate cancer. Minomic is currently launching MiCheck® Prostate in Australia, the U.S. and China, which can reduce unnecessary biopsies and assist clinicians in determining the risk of men having aggressive prostate cancer. For more information on Minomic see . Contacts

Minomic International Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Minomic International Rank

Minomic International Frequently Asked Questions (FAQ)

  • Where is Minomic International's headquarters?

    Minomic International's headquarters is located at 75 Talavera Road, Macquarie Park.

  • What is Minomic International's latest funding round?

    Minomic International's latest funding round is Unattributed.

  • How much did Minomic International raise?

    Minomic International raised a total of $6.8M.

  • Who are the investors of Minomic International?

    Investors of Minomic International include Probiomics and NuSep.

  • Who are Minomic International's competitors?

    Competitors of Minomic International include btt, iMMCO Diagnostics, Epocal, Clarient, Bg Medicine and 11 more.

Compare Minomic International to Competitors

Sensys Medical

Sensys Medical develops medical diagnostic instruments

LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

Switcher Logo

Switcher develops and commercializes easy-to-use in vitro diagnostic urine tests


Biopticon Corporation is aimed to develop medical diagnostic devices using laser, photonics and image processing based technologies.


Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.